RUCONEST® business performed strongly in 2Q 2023; continue to anticipate low single digit annual revenue growth Strong start to U.S. Joenja® launch during 2Q.
FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues.
/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") ( Euronext: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year.
LEIDEN, Netherlands, March 16, 2023 /PRNewswire/ Total revenues increased by 3% to US$205.6 million, in line with single digit growth guidanceOperating profit increased by 34% to US$18.2
/PRNewswire/ Total revenues increased by 3% to US$205.6 million, in line with single digit growth guidance Operating profit increased by 34% to US$18.2.